BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/29/2024 6:08:22 AM | Browse: 109 | Download: 614
 |
Received |
|
2024-04-15 13:02 |
|
Peer-Review Started |
|
2024-04-15 13:02 |
|
First Decision by Editorial Office Director |
|
2024-08-03 03:34 |
|
Return for Revision |
|
2024-08-06 01:02 |
|
Revised |
|
2024-08-18 14:43 |
|
Publication Fee Transferred |
|
2024-09-04 05:37 |
|
Second Decision by Editor |
|
2024-08-29 02:38 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-08-29 09:12 |
|
Articles in Press |
|
2024-08-29 09:12 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-09-19 07:24 |
|
Publish the Manuscript Online |
|
2024-09-29 06:08 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiao-Qian Li, Jing Yang, Bo Liu and Shu-Mei Han |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Shu-Mei Han, PhD, Associate Chief Physician, Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440 Jiyan Highway, Huaiyin District, Jinan 510000, Shandong Province, China. 15553115908@163.com |
| Key Words |
Human epidermal growth factor receptor 2-positive gastric cancer; RC48; Apatinib; Combination therapy; Progression-free survival |
| Core Tip |
Apatinib exhibits synergistic effect with pan-HER inhibitor and reverses acquired resistance in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) via stem cell factor/c-kit signaling and its downstream pathways. The patient treated with HER2-targeted therapy (disitamab vedotin, RC48) and small molecule antiangiogenesis targeted therapy with apatinib experiencing excellent survival, which provide related data for posterior line treatment of advanced GC. |
| Publish Date |
2024-09-29 06:08 |
| Citation |
Li XQ, Yang J, Liu B, Han SM. Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature. World J Clin Oncol 2024; 15(10): 1351-1358 |
| URL |
https://www.wjgnet.com/2218-4333/full/v15/i10/1351.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v15.i10.1351 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
